Table 3.
Dysregulated pathways specific to WT microglia in response to CPZ exposure in vivo.
| WT specific KEGG pathways | FDR | Changed pathway members |
|---|---|---|
| Valine, leucine and isoleucine degradation | 6.4e-06 | Abat, Acaa2, Acat1, Aldh3a2, Aldh6a1, Dld, Ivd, Pccb |
| Proteasome | 2.74e-05 | Psma5, Psmb10, Psmb6, Psmb8, Psme1, Psme2, Psme3 |
| Alzheimer s disease | 0.00017 | Apoe, Atp5a1, Atp5c1, Atp5j, Cox7a2, Ndufa4, Ndufv1, Sdha, Uqcrc1, Uqcrc2, Uqcrfs1 |
| Antigen processing and presentation | 0.00069 | Canx, Ctsb, Ctsl, Hspa4, Psme1, Psme2, Psme3 |
| mRNA surveillance pathway | 0.0022 | Dazap1, Nudt21, Ppp1ca, Ppp1cb, Ppp1cc, Rnmt, Wdr82 |
| Glyoxylate and dicarboxylate metabolism | 0.0039 | Acat1, Aco2, Cat, Pccb |
| Amino sugar and nucleotide sugar metabolism | 0.0049 | Cmas, Cyb5r3, Hexa, Hexb, Hk1 |
| beta-Alanine metabolism | 0.0082 | Abat, Aldh3a2, Aldh6a1, Cndp2 |
| Oocyte meiosis | 0.19 | Ppp1ca, Ppp1cb, Ppp1cc, Smc1a, Smc3, Ywhab |
| Fatty acid degradation | 0.031 | Acaa2, Acat1, Aldh3a2, Eci1 |
| Cardiac muscle contraction | 0.22 | Atp1b1, Cox7a2, Uqcrc1, Uqcrc2, Uqcrfs1 |
| Non-alcoholic fatty liver disease (NAFLD) | 0.23 | Cox7a2, Ndufa4, Ndufv1, Sdha, Uqcrc1, Uqcrc2, Uqcrfs1 |
| Protein export | 0.25 | Spcs1, Spcs2, Spcs3 |
| Herpes simplex infection | 0.28 | C1qbp, C3, Gtf2i, Hcfc1, Ppp1ca, Ppp1cb, Ppp1cc, Srsf7 |
| RNA transport | 0.32 | Kpnb1, Nup155, Nup210, Ranbp2, Thoc2, Thoc6, Tpr |
| Collecting duct acid secretion | 0.32 | Atp6v1e1, Atp6v1f, Atp6v1g1 |